Advertisement
  • Taking Drug Dosing Off Autopilot

    Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.

    by Marcus A. Banks

  • Beating the Bully Inside

    To gain control over fear of my breast cancer recurring, I called on lessons learned as a 5-year-old confronting the neighborhood bully.

    by Joan Harris

  • More Choices to Treat Lung Cancer

    Advances in precision medicine and immunotherapy have led to better treatments for many patients with advanced lung cancer. But having a wider selection of therapies to choose from can make treatments more complex.

    by Kendall K. Morgan

  • Survivor Profile

    An Unlikely Pivot

    Medha Deoras-Sutliff's experience with breast cancer fueled her interest in advocacy for breast cancer patients and, more recently, her support for research on rare cancers.

    by Lindsey Konkel

  • Learning Medicare’s ABCDs

    Medicare was established to help provide affordable health care coverage for older Americans. But Medicare beneficiaries with cancer can still face financial burdens related to their care.

    by Kate Yandell

  • Q&A

    The Lost Poetry of Patient Stories

    Medical histories capture a vital snapshot of a patient's health status. In his new book, hematologist-oncologist Mikkael A. Sekeres provides a richer narrative.

    by Marci A. Landsmann

  • Forward Look

    What’s Next? Fall 2020

    A therapeutic vaccine targeting advanced cervical cancer.

    by Anna Azvolinsky

  • Worth the Wait

    Neoadjuvant therapy—using treatments such as chemotherapy, hormone therapy or radiation to shrink a tumor or treat unseen metastases before surgery—can improve outcomes for some patients.

    by Sharon Tregaskis

  • Planning to Survive

    Survivorship care plans can prepare cancer patients to get the best medical care and maintain their quality of life following treatment.

    by Carly Flumer

  • Targeted Therapy for Early-Stage Lung Cancer?

    A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

    by Ashley P. Taylor